Christian B. Dinneen-Long
Consigliere Generale presso GLYCOMIMETICS, INC.
Posizioni attive di Christian B. Dinneen-Long
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Consigliere Generale | 29/04/2019 | - |
| Segretario Aziendale | 29/04/2019 | - |
Storia della carriera di Christian B. Dinneen-Long
Precedenti posizioni note di Christian B. Dinneen-Long
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Consigliere Generale | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Consigliere Generale | - | - |
| Medimmune, Inc. | Consigliere Generale | - | - |
Formazione di Christian B. Dinneen-Long
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
